Effect of Imidazole on the Solubility of a His-Tagged Antibody Fragment

Hybridoma and Hybridomics

Volumn 22, Issue 6, 2003, Pages 347-355

  Hamilton, Stephen ^a   Odili, Joy ^a   Pacifico, Marc D ^a   Wilson, George D ^a   Kupsch, Jörg M ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID DERIVATIVE; ANTIBODY; BUFFER; DETERGENT; HISTIDINE; IMIDAZOLE; METAL ION; PROTEOGLYCAN; RECOMBINANT PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHEMICAL MODIFICATION; CONTROLLED STUDY; CROSS LINKING; DIALYSIS; GENETIC ENGINEERING; ISOTOPE LABELING; LEACHING; MELANOMA; MOUSE; NONHUMAN; PH; PRECIPITATION; PRIORITY JOURNAL; PROTEIN STABILITY; SOLUBILITY; STORAGE;

ANIMALIA;

EID: 0346394004     PISSN: 15368599     EISSN: None     Source Type: Journal    
DOI: 10.1089/153685903771797048     Document Type: Article

References (37)

1. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan GS, and Whitlow M: 1988. Single-chain antigen-binding proteins. Science 1988;242:423-426. [Erratum in Science 1989;244:409.]
2. Bird RE, and Walker BW: Single chain antibody variable regions. Trends Biotechnol 1991;9:132-137.
3. Begent RH, Verhaar MJ, Chester KA, Casey JL, Green AJ, Napier MP, Hope-Stone LD, Cushen N, Keep PA, Johnson CJ, Hawkins RE, Hilson AJ, and Robson L: Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med 1996;2:979-984.
4. Mayer A, Tsiompanou E, O'Malley D, Boxer GM, Bhatia J, Flynn AA, Chester KA, Davidson BR, Lewis AA, Winslet MC, Dhillon AP, Hilson AJ, and Begent RH: Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody. Clin Cancer Res 2000;6:1711-1719.
5. Reiter Y, and Pastan I: Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Trends Biotechnol 1998;16:513-520.
6. Larson SM, El-Shirbiny AM, Divgi CR, Sgouros G, Finn RD, Tschmelitsch J, Picon A, Whitlow M, Schlom J, Zhang J, and Cohen AM: Single chain antigen binding protein (sFv CC49) first human studies in colorectal carcinoma metastatic to liver. Cancer 1997;80(Suppl):2458-2468.
7. Nieba L, Honegger A, Krebber C, and Plückthun A: Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. Protein Eng 1997;10:435-444.
8. Riechmann L, and Muyldermans S: Single domain antibodies: comparison of camel VH and camelized human VH domains. J Immunol Methods 1999;231:25-38.
9. Tan PH, Chu V, Stray JE, Hamlin, DK, Pettit D, Wilbur DS, Vessella RL, and Stayton PS: Engineering the isoelectric point of a renal cell carcinoma targeting antibody greatly enhances scFv solubility. Immunotechnology 1998;4:107-114.
10. Porath J, Carlsson J, Olsson I, and Belfrage G: Metal chelate affinity chromatography, a new approach to protein fractionation. Nature 1975;258:598-599.
11. Porath J: Immobilized metal ion affinity chromatography. Protein Exp Purif 1992;3:263-281.
12. Warwicker J, and O'Connor J: A model for vicilin solubility at mild acidic pH, based on homology modelling and electrostatics calculations. Protein Eng 1995;8:1243-1251.
13. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, Hartshorn MA, Tanzi RE, and Bush AI: Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 1998;273:12817-12826.
14. Khossravi M, Shire SJ, and Borchardt RT: Evidence for the involvement of histidine A(12) in the aggregation and precipitation of human relaxin induced by metal-catalyzed oxidation. Biochemistry 2000;39:5876-5885.
15. Kang N, Hamilton S, Sanders R, Wilson GD, and Kupsch JM: In vivo targeting of malignant melanoma by 125-I and 99m-Tc labelled single-chain Fv against high molecular weight melanoma associated antigen. Clin Cancer Res 2000;6:4921-4931.
16. Pluschke G, Vanek M, Evans A, Dittmar T, Schmid P, Itin P, Filardo EJ, and Reisfeld RA: Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc Natl Acad Sci USA 1996;93:9710-9715.
17. Kupsch JM, Tidman NH, Kang NV, Truman H, Hamilton S, Patel N, Newton Bishop JA, Leigh IM, and Crowe JS: Isolation of human tumor-specific antibodies by selection of an antibody phage library on melanoma cells. Clin Cancer Res 1999;5:925-931.
18. Kozlowski JM, Fidler IJ, Campbell D, Xu ZL, Kaighn ME, and Hart IR: Metastatic behavior of human tumour cell lines grown in the nude mouse. Cancer Res 1984;44:3522-3529.
19. Kupsch JM, Tidman N, Bishop JA, McKay I, Leigh I, and Crowe JS: 1995. Generation and selection of monoclonal antibodies, single-chain Fv and antibody fusion phage specific for human melanoma-associated antigens. Melanoma Res 1995;5:403-411.
20. Kang NV, Hamilton S, Sanders R, Wilson GD, and Kupsch JM: Efficient in vivo targeting of malignant melanoma by single-chain Fv antibody fragments. Melanoma Res 1999;9:545-556.
21. Kipriyanov SM, Moldenhauer G, and Little M: High level production of soluble single chain antibodies in small-scale Escherichia coli cultures. J Immunol Methods 1997;200:69-77.
22. Bowden GA, and Georgiou G: Folding and aggregation of beta-lactamase in the periplasmic space of Escherichia coli. J Biol Chem 1990;265:16760-16766.
23. Skerra A, and Plückthun A: Secretion and in vivo folding of the Fab fragment of the antibody McPC603 in Escherichia coli: influence of disulphides and cis-prolines. Protein Eng 1991;4:971-979.
24. Sawyer JR, Schlom J, and Kashmiri SV: The effects of induction conditions on production of a soluble anti-tumor sFv in Escherichia coli. Protein Eng 1994;7:1401-1406.
25. Kiefhaber T, Rudolph R, Kohler HH, and Buchner J: Protein aggregation in vitro and in vivo: a quantitative model of the kinetic competition between folding and aggregation. Bio/Technology 1991;9:825-829.
26. Frigon RP, and Lee JC: The stabilization of calf-brain microtubule protein by sucrose. Arch Biochem Biophys 1972;153:587-589.
27. Arakawa T, and Timasheff SN: The mechanism of action of Na glutamate, lysine HCl, and piperazine-N,N′-bis (2-ethanesulfonic acid) in the stabilization of tubulin and microtubule formation. J Biol Chem 1984;259:4979-4986.
28. Na GC, and Timasheff SN: Interaction of calf brain tubulin with glycerol. J Mol Biol 1981;151:165-178.
29. Arakawa T, and Timasheff SN: Mechanism of poly(ethylene glycol) interaction with proteins. Biochemistry 1985;24:6756-6762.
30. Kreilgaard L, Jones LS, Randolph TW, Frokjaer S, Flink JM, Manning MC, and Carpenter JF: Effect of Tween 20 on freeze-thawing- and agitation-induced aggregation of recombinant human factor XIII. J Pharm Sci 1998;87:1597-1603.
31. Harris E, and Augal S: Concentration of the extract. In: Protein Purification Methods. Harris E (Ed.). IRL Press, Oxford, 1989, pp. 125-174.
32. Parks TD, Smith HA, and Dougherty WG: Cleavage profiles of tobacco etch virus (TEV)-derived substrates mediated by precursor and processed forms of the TEV NIa proteinase. J Gen Virol 1992; 73:149-155.
33. Parks TD, Leuther KK, Howard ED, Johnston SA, and Dougherty WG: Release of proteins and peptides from fusion proteins using a recombinant plant virus proteinase. Anal Biochem 1994;216:413-417.
34. Matthews JM, Ward LD, Hammacher A, Norton RS, and Simpson RJ: Roles of histidine 31 and tryptophan 34 in the structure, self-association, and folding of murine interleukin-6. Biochemistry 1997;36:6187-6196.
35. Wade TR, Jones HE, and Chanda JJ: Intravenous miconazole therapy of mycotic infections. Arch Intern Med 1979;139:784-786.
36. Sohn CA: Evaluation of ketoconazole. Clin Pharm 1982;1:217-224.
37. Waibel R, Alberto R, Willuda J, Finnern R, Schibli R, Stichelberger A, Egli A, Abram, U, Mach, JP, Plückthun A, and Schubiger PA: Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat Biotechnol 1999;17:897-901.